Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML

Trial Profile

Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Cytarabine (Primary) ; Vosaroxin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Therapeutic Use
  • Acronyms VITAL
  • Most Recent Events

    • 08 May 2017 According to a Sunesis Pharmaceuticals media release, this trial has progressed from Stage 1 to Stage 2. 17 patients enrolled in Stage 1 and, following a one-time interim analysis by the Data Safety Monitoring Board of responses exceeding a pre-defined efficacy threshold, is now proceeding to enroll 24 patients in Stage 2.
    • 24 Mar 2016 According to a Sunesis Pharmaceuticals media release, the first patients have been treated in this trial.
    • 11 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top